

# Mesoblast

Phase III study start

## Positive data in discogenic low back pain

Mesoblast has reported positive results from its 100-patient Phase II trial of mesenchymal precursor cells (MPCs) in patients with chronic moderate-to-severe discogenic low back pain. The data show strong indications of sustained efficacy across a broad range of clinical and radiographic parameters and support a planned move into Phase III studies. We maintain our recently increased valuation of A\$3.0bn (A\$9.06/diluted share), noting that the use of a higher probability (50%) to reflect a possible Phase III start of the two spinal programmes would increase the rNPV to A\$3.2bn or A\$10.04/share.

Year end	Revenue (A\$m)	PBT* (A\$m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
06/12	27.8	(38.6)	(21.6)	0.0	N/A	N/A
06/13	24.2	(48.8)	(17.2)	0.0	N/A	N/A
06/14e	16.2	(76.9)	(24.1)	0.0	N/A	N/A
06/15e	16.2	(82.1)	(25.6)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

## Positive 12-month results in disc repair

Mesoblast has reported highly positive 12-month results from its 100-patient Phase II trial of MPCs in patients with chronic moderate-to-severe discogenic low back pain. The data show strong indications of sustained efficacy across a broad range of clinical and radiographic parameters after a single intra-disc injection and support the planned move into Phase III studies. Mesoblast intends to meet with regulatory authorities shortly to discuss the design of the registration trial.

## Plan to start Phase III studies

The disc repair programme is one of two spinal programmes with MPC, both of which are proprietary (ie they fall outside the scope of the alliance with Teva). The second is the use of MPCs for lumbar spinal fusion. Both programmes may enter Phase III trials late this year, depending on the outcome of partnership discussions.

## Teva moving ahead in CHF

Meanwhile, Mesoblast's partner Teva is set to recruit the first patients into its pivotal Phase III study of MPCs, coded as CEP-41750, in congestive heart failure (CHF), possibly as early as this week. CHF is the most important of the seven different indications being pursued with the MPC platform and, with US\$4bn peak sales potential, it represents the largest component in our valuation.

## Valuation: rNPV of A\$3.0bn (A\$9.06/diluted share)

Edison maintains its recently updated valuation of A\$3.0bn (A\$9.34/share basic or A\$9.06/share fully diluted). The potential start of Phase III trials in disc repair and spinal fusion would be allow for the use of a higher probability (50%) and increase the rNPV to A\$3.2bn or A\$10.04/share.

Pharma & biotech

4 February 2014

Price **A\$6.0**

Market cap **A\$1,927m**

US\$0.92/A\$

Net cash (A\$m) as at 30 September 2013 292

Shares in issue 321.1m

Free float 60%

Code MSB

Primary exchange ASX

Secondary exchange OTC Pink

### Share price performance



% 1m 3m 12m

Abs 2.2 (9.4) (3.8)

Rel (local) 5.2 (5.8) (8.6)

52-week high/low A\$7.5 A\$5.1

### Business description

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas: immunologic/inflammatory (Phase III), spine disease (Phase II), cardiovascular (Phase III) and cancer (Phase III). The CV and BMT areas are partnered with Teva, and worldwide manufacturing of MPCs will be provided by Lonza.

### Next events

Phase III plans in disc repair H214

Update on Phase II trial of MPCs in AMI 2014

### Analysts

Chris Kallos +61 (0)2 9258 1160

Robin Davison +44 (0)20 3077 5737

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

## Mesoblast datasheet

Exhibit 1: Clinical-stage pipeline (summary)				
Platform (product),	Indications	Dose (delivery)	Status	Next milestones
<b>Cardiovascular</b>				
MPCs/(CEP-41750) <b>Teva</b>	CHF	150m MPCs (transendocardial injection)	1,730-pt <a href="#">Phase III study</a>	Q114: starts US enrolment, H214: start EU enrolment
MPCs, <b>Teva</b>	Acute myocardial infarction (AMI)	12.5m or 25m MPCs (intracoronary infusion)	225-pt <a href="#">Phase II study</a> ongoing	2014: update on study 2015: headline data
<b>Spinal disease</b>				
MPCs (NeoFuse)	Lumbar spinal fusion	25m or 75m MPCs (implanted into intervertebral disc space)	24-pt Phase II completed	H214: potential Phase III trial
MPCs	Lumbar intervertebral disc repair	6m or 18m MPCs (intradiscal injection)	100-pt <a href="#">Phase II</a> complete.	H214: potential Phase III start
<b>Immunologic/Inflammatory</b>				
MSCs (Prochymal, remestemcel-L)	Moderate-to-severe Crohn's disease (CD)	600m or 1,200m MSCs (intravenous infusion)	330-pt Phase III study ongoing	H214: complete Phase III recruitment
MPCs	Type 2 diabetes and diabetic nephropathy (DN)	Diabetes trial: 0.3m, 1m, or 2m MPC/kg (IV infusion); DN trial: 150m or 300m MPCs (IV injection)	60-pt Phase I/II study diabetes shows some evidence of efficacy. DN trial: 30-pt Phase II study ongoing	Q314: headline results from DN study
MPCs	Biologic refractory rheumatoid arthritis	Xm MPCs (IV injection)	48-pt <a href="#">Phase I/II study</a>	H115: headline results
<b>Oncology</b>				
MSCs (Prochymal), <b>JCR Pharma</b>	Steroid-refractory acute graft versus host disease (aGvHD)	2m cells/kg twice weekly for four weeks (IV infusion)	Canadian/New Zealand conditional approval. Expanded Access Treatment in US. 190-pt Phase III aGvHD study and 240-pt Phase III steroid-refractory aGvHD study completed	Q114: Japanese filing by JCR H114: regulatory discussions (FDA, EMA) regarding potential filings
MPCs, <b>Teva</b>	Bone marrow transplantation (BMT)	One MPC expanded cord unit (IV infusion)	240-pt <a href="#">Phase III study</a> ongoing	H217/H118: headline results

Source: Edison Investment Research

### Exhibit 2: Mesoblast strategic partnerships

Partner/deal	Terms
<b>Teva/Exclusive rights to selected CV, cancer and neurologic indications of MPCs</b>	Teva has exclusive development and marketing rights, and is responsible for funding all late-stage development (Phase IIb, Phase III) and commercialisation. Mesoblast retains all manufacturing rights and has a negotiated a transfer price based on a percentage (Edison assumes 40%) of net in-market sales. Up to US\$1.7bn in milestones are payable triggered by regulatory approvals for each product/indication in major territories (approval for CHF in US and EU triggers estimated payments of US\$150m and US\$100m, respectively). Teva holds a 17.6% equity stake in Mesoblast.
<b>Lonza/Strategic alliance for supply MPC products</b>	Long-term supply agreement with exclusive access to Lonza's Singapore manufacturing facility. Mesoblast has the option to require Lonza to construct a purpose-built manufacturing facility for exclusive use and in return would be obligated to purchase agreed quantities of marketed products. Mesoblast can also buy out this facility at a pre-agreed purchase price two years after it receives regulatory approval. The FDA has approved Lonza's manufacturing process to supply MPC products for US Phase III trials from both its Singapore and US facilities. Stockpiles of product to FDA specification are currently adequate for the next 12 months of Phase III trials.
<b>JCR Pharmaceuticals/ Prochymal for aGvHD in Japan</b>	JCR has exclusive Japanese rights to manufacture, develop and market Prochymal (known as JR-031) for steroid-refractory aGvHD. The annual number of hematopoietic stem cell transplants (HSCT) in Japan is c 3,500, of which a substantial proportion are likely to be autologous at risk of subsequent aGvHD. JCR will bear all costs of bringing Prochymal to market. Mesoblast is entitled to (undisclosed) milestones on regulatory filing and approval, milestones on achievement of pre-determined net sales levels, plus future royalties. JCR plans to file for Japanese approval under the existing regulatory pathway by March 2014.

Source: Edison Investment Research

### Exhibit 3: CEP-41750 Phase III trial design

<b>Design</b>	Multi-centre, randomised (1:1), double-blind, sham procedure-controlled Phase III trial in 1,730 subjects with CHF. Pts will receive a single dose of 150m MPCs administered by transendocardial injection (direct injection into left ventricle of the heart via NOGA catheter) or undergo a cardiac catheterisation involving a sham cardiac mapping and cell delivery procedure.
<b>Endpoint</b>	<b>Primary:</b> Time-to-event analysis of HF-MACE (includes cardiac death, resuscitated cardiac death, or non-fatal decompensated heart failure events). Study is powered to show a 25% relative reduction in primary endpoint (HF-MACE) for Revascor vs control – assumes c 20% event rate in controls and c 15% event rate on CEP-41750. <b>Secondary:</b> Various measures of heart function, changes in NYHA functional class and QoL questionnaires.
<b>Interim analysis</b>	Two planned interim efficacy and/or safety analyses: first analysis (not futility) after c 18 months will assess various efficacy and safety parameters to determine the risk/benefit ratio; second analysis (futility) on HF-MACE endpoint after c 30 months, at which time the majority (>60%) of pts will have been recruited and c 40% of expected HF-MACE events occurred.
<b>Patient population</b>	NYHA class II and III systolic heart failure (LVEF≤40%) of ischaemic or non-ischaemic origin.
<b>Recruitment/timing</b>	Initial recruitment in US, with European enrolment commencing in H214. Number of centres not known, but assumed to be large. A final readout of data is indicated for mid (July/August) 2018. US/EU approvals/launch could take place in H119.

Source: Edison Investment Research

## Update: Positive results in disc repair

Mesoblast has announced positive 12-month results from its 100-patient Phase II trial of mesenchymal precursor cells (MPCs) in patients with chronic moderate-to-severe discogenic low back pain (ie lumbar degenerative disc disease or DDD). The data show strong indications of sustained efficacy across a broad range of clinical and radiographic parameters after a single intra-disc injection and support a planned move into Phase III studies. Mesoblast intends to meet with regulatory authorities shortly to discuss the design of the registration trial in this indication.

The Phase II trial enrolled 100 patients with moderate to severe low back pain, caused by early disc degeneration (less than 30% disc height loss, 83% below Pfirrmann Grade 5 by MRI). Enrolled subjects had chronic low back pain (>six months) due moderate DDD in the lumbar spine (from L1 to S1), which was unresponsive to three months of conservative therapy (including physiotherapy). Patients were randomised to one of four treatment groups, two control (saline and hyaluronic acid or HA) and two active (6m MPCs and 18m MPCs). Patients will be evaluated for safety and efficacy over a total of 36 months to evaluate long-term treatment effects.

Results from the 12 month evaluation are shown in Exhibit 4. The large majority of the outcome measures showed a statistically significant improvement vs controls with MPC-treated patients using less opioids for pain relief, achieving greater radiographically-determined disc stability and a lower requirement for additional surgical and non-surgical treatment interventions. From a clinical perspective, MPC was equally effective at the lower and higher dose.

**Exhibit 4: Outcome data at 12 months**

Outcome measure	Saline (n=20)	HA (n=20)	6m MPCs (n=30)	18m MPCs (n=30)
<b>Improvement in chronic low back pain</b>				
Reduction in mean pain score (VAS) vs baseline	27 points	27 points	37 points, p=0.11*	40 points, p=0.046*
Prop of pts achieving >50% reduction in pain score	31%	35%	69%, p=0.009	62%, p=0.038
Prop of pts achieving minimal residual back pain (VAS<20)	18% (pooled)		52%, p=0.01	42%, p=0.05
Mean daily opioid use, tablet/day	1.00	0.94	0.77	0.58, p=0.17 vs saline
Mean opioid use in pts achieving >50% reduction in pain score	1.3	1.2	0.7	0.6
Need for additional surgical/non-surgical intervention for persistent pain	25%	10%	6.9% (p<0.05)*	3.3% (p<0.05)*
Time to first additional treatment intervention	N/A	N/A	p=0.023 vs saline	p=0.010 vs saline
<b>Improvement in function</b>				
Reduction in mean disability score (Oswestry Disability Index, ODI)	28%	30%	35%	43%, p=0.09 vs saline
Prop of pts achieving min residual functional disability (ODI score <20)	18% (pooled)		36%, p=0.14	39%
<b>Improvement in disc stability</b>				
Reduction in radiographically-determined translational movement of the disc	3.5%	2.5%	2.0%	1.3%, p=0.021

Source: Mesoblast. Note: \*Vs pooled controls.

Discogenic back pain is the result of a complex process initiated by degeneration and loss of proteoglycan and water content of the nucleus pulposus, and increased stress on and fissure formation of the annulus fibrosis. Treatment varies from conservative options (analgesia, anti-inflammatory agents, epidural steroid injection) to surgical intervention (spine fusion, discectomy or artificial disc replacement).

While the majority of patients are treated non-surgically, more severe cases may require surgery. Chronic lower back pain can result from a wide variety of conditions including DDD. Major risk factors are age, genetics and mechanical injury/stresses to the disc. This leads to structural disruption and cell-mediated changes in disc composition. Some 30m people in the US suffer from lower back pain, of which c 15% (c 4.5m) fail to respond to conservative therapy. A proportion (c 500,000) has severe DDD that warrants surgery, which leaves c 4m with limited options. We estimate that 25% (c 1m) have moderate DDD that could be targeted with MPC injections. Exhibit 5 outlines our key model assumptions for MPCs in DDD.

**Exhibit 5: Edison forecast assumptions for MPC in intervertebral disc repair**

	US	Europe	Total	Notes
Addressable market – 2013	1m	1.5m	2.5m	
Launch year (FY)	2018	2018		
Peak year (FY)	2023	2023		Peak sales at year six post launch.
Peak market share, n (%)	20%	20%		Limited non-surgical treatment options for moderate lumbar DDD.
Pricing (US\$)	5,000	3,750		Medtronic's InFuse (BMP-2) typically costs c US\$5,000 in the US.
Peak in-market sales (US\$m)	1,210	621	1,831	
Peak revenues to Mesoblast (US\$m)	363	186	549	Assumes product is partnered before/during Phase III development. Forecast transfer price equivalent to 30% of net sales price.

Source: Edison Investment Research

## Spinal fusion programme

The disc repair programme is one of two spinal programmes with MPC, both of which are proprietary (ie they fall outside the scope of the alliance with Teva). The second is the use of MPCs for lumbar spinal fusion. Both programmes may enter Phase III trials later this year.

Lumbar spinal fusion surgery is undertaken in patients who have severe lower back and/or neurological deficits that have not responded to conservative treatment. It is considered in conditions such as severe DDD, spinal disc herniation and spondylolisthesis (slipped disc). The procedure is to fuse two or more lumbar vertebrae, eliminating motion between them and decreasing pain from the joint. This is achieved by surgical placement of bone – an autograft (from the hip) or allograft (donor bone or demineralised bone matrix [DBM]) – or a bone-replacement (bone morphogenetic protein) between the vertebrae. This stimulates the body's natural bone growth processes.

The standard against which all bone grafts are measured is autograft. However, because a procedure is required to harvest bone (from the hip) potential drawbacks include: poor candidate for harvesting, a longer surgical procedure, harvest-site infection, increased recovery time and long-term pain. An alternative to bone grafting is NuVasive's Osteocel Plus, an allograft cellular matrix that contains living bone cells (mesenchymal stem cells, osteoprogenitor cells) and a DBM scaffold. Osteocel is not FDA regulated (it came to market via the HCT/P pathway) and did not undergo extensive clinical trials.

Results of a Phase II FDA study of MPCs in lumbar fusion that were reported last year showed comparable efficacy and safety outcomes to autograft without the requirement for a bone-harvesting procedure (and its associated risks). The open-label study recruited 24 patients undergoing 1- or 2-level (ie two or three vertebrae) lumbar interbody fusion via posterior procedures. Enrolled subjects had lumbar DDD, clinical symptoms of neurogenic pain, and failed six months of conservative therapy. Patients were randomised to receive 25m MPC (n=8), 75m MPC (n=8) or autograft (n=8), with the latter taken from the patient's hip (iliac crest). Results from 23 patients were available at 12 months and are shown in Exhibit 6.

**Exhibit 6: Phase II results in lumbar spinal fusion**

Spinal fusion success	Comparable rates of fusion for all three groups, although 25m (7 pts, 86%) was slightly better than autograft (6 pts, 75%) and 75m (five pts, 63%).
Pain relief	MPCs (both doses) and autograft offered similar improvements in back pain relief at 12 and 24 months.
Blood loss	Significantly lower (30-43%) reduction in blood loss versus autograft, although we view the absolute reduction (120-170ml) as unlikely to be clinically meaningful. The higher blood loss for autograft likely relates to the surgical harvesting of iliac crest bone.
Safety	No reoperations/revisions in any groups, similar AE rate across all groups, no treatment-related SAEs, no heterotopic (abnormal) bone formation, and no immune responses.

Source: Edison Investment Research

An estimated 1.7m spinal fusion procedures were performed globally in 2011, of which 1m (c 60%) were lumbar. The US represents the largest market with c 380k lumbar fusions undertaken in 2012. We estimate that posterior approaches account for c 60% (228k) of procedures. In Europe, we estimate that c 350k lumbar fusions are undertaken annually, resulting in c 175k posterior

approaches. As a cross reference for Europe, recent UK data (2010/11) indicate that c 35k surgical procedures are undertaken annually in the UK for back pain or radicular pain, the majority of which are lumbar fusions/decompressions.

**Exhibit 7: Edison forecast assumptions for MPCs in lumbar spinal fusion**

	US	Europe	Total	Notes
Addressable market – 2013	230k	170k	400k	US: estimated 380k lumbar spinal fusions, of which 60% (230k) posterior approaches. EU: estimated 350k lumbar fusions, with 60% (175k) posterior.
Launch year (FY)	2019	2019		Assumes Phase III start in 2014, data 2017, submission 2018, approval/launch H119.
Peak year (FY)	2024	2024		Peak sales at year six post launch.
Peak market share, n (%)	40%	40%		Unmet need for alternative spinal fusion products that are safer (than Medtronic's InFuse), more convenient (than autografts) and better regulated (than Osteoecel).
Pricing (US\$)	5,000	3,750		MPC dose is 25m or 75m on carrier graft. Medtronic's InFuse (BMP-2) typically costs c US\$5,000 in the US.
Peak in-market sales by partner (US\$m)	590	293	883	Peak sales of InFuse were c US\$900m. Global market for bone graft substitutes US\$1.6bn in 2012 (70% from spinal fusions)
Peak revenues to MSB (US\$m)	177	88	265	Assumes NeoFuse is partnered before/during Phase III trial. Forecast transfer price equivalent to 30% of net sales price.

Source: Edison Investment Research

## Sensitivities

Mesoblast remains subject to the risks typically associated with biotech company drug development, including the possibility of unfavourable outcomes in clinical trials and regulatory reviews, success of competitors, and commercial decisions by partners or potential partners. The key stock-specific sensitivity is the future of the Teva alliance – this partnership underwrites the development of MPCs in three major therapeutic areas (CHF, AMI and BMT).

## Valuation

Edison maintains its recently updated valuation of A\$3.0bn (A\$9.34/share basic or A\$9.06/share fully diluted). The potential start of Phase III trials in disc repair and spinal fusion would allow for the use of a higher probability (50%) and increase the rNPV to A\$3.2bn or A\$10.04/share.

## Financials

Mesoblast has filed an Appendix 3c, which shows that cash was A\$250m as of 30 December. We have adjusted our financial model to reflect a higher manufacturing and commercialisation spend, now A\$35m, than was previously modelled (A\$23m), in the light of the A\$17.5m spent in H1. Forecast R&D spend is unchanged at A\$47.4m for FY14 (A\$21.5m was spent in H1) and A\$47.9m in FY15. On this basis, operating cash outflow would be c A\$94-95m/year over the next three years. In the absence of additional financing and/or partnerships, our model now suggests the cash runway extends into FY17.

Revenues principally comprise staged recognition of the US\$130m Teva upfront (A\$16.2m/year). We have not modelled any revenue from partnering of spinal indications, but assume that potential future partners would fund all or part of Phase III trials or G&A.

**Exhibit 8: Financial summary**

	A\$'000s	2011	2012	2013	2014e	2015e
30-June		IFRS	IFRS	IFRS	IFRS	IFRS
<b>PROFIT &amp; LOSS</b>						
Revenue		116,221	27,808	24,185	16,176	16,176
Cost of Sales		0	0	0	0	0
Gross Profit		116,221	27,808	24,185	16,176	16,176
R&D Expenses		(11,948)	(36,937)	(43,108)	(47,419)	(47,893)
SG&A Expenses		(11,792)	(28,051)	(30,734)	(32,271)	(32,593)
EBITDA		90,238	(48,764)	(58,668)	(86,520)	(87,626)
Operating Profit (before amort and except)		90,103	(49,078)	(59,338)	(87,223)	(88,365)
Intangible Amortisation		(44)	(65)	(102)	(107)	(112)
Exceptionals		0	0	0	0	0
Share-based payments		(2,465)	(10,052)	(11,163)	(11,163)	(11,163)
Operating Profit		87,595	(59,195)	(70,603)	(98,493)	(99,640)
Net Interest		4,648	10,472	10,526	10,277	6,256
Profit Before Tax (norm)		94,751	(38,606)	(48,812)	(76,946)	(82,109)
Profit Before Tax (FRS 3)		92,243	(48,723)	(60,077)	(88,216)	(93,384)
Tax		(1,634)	(22,422)	(1,585)	0	0
Profit After Tax (norm)		93,117	(61,028)	(50,397)	(76,946)	(82,109)
Profit After Tax (FRS 3)		90,609	(71,145)	(61,662)	(88,216)	(93,384)
Average Number of Shares Outstanding (m)		216.8	282.9	292.8	318.8	321.2
EPS - normalised (c)		42.95	(21.58)	(17.21)	(24.13)	(25.56)
EPS - normalised and fully diluted (c)		40.88	(20.78)	(16.60)	(23.34)	(24.73)
EPS - (IFRS) (c)		41.79	(25.15)	(21.06)	(27.67)	(29.07)
Dividend per share (c)		0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		100.0	100.0	100.0	100.0	100.0
EBITDA Margin (%)		N/A	N/A	N/A	N/A	N/A
Operating Margin (before GW and except) (%)		N/A	N/A	N/A	N/A	N/A
<b>BALANCE SHEET</b>						
Fixed Assets		497,755	503,877	551,868	552,389	552,874
Intangible Assets		475,326	497,219	547,834	547,834	547,834
Tangible Assets		609	1,998	2,757	3,278	3,763
Investments		21,820	4,660	1,277	1,277	1,277
Current Assets		265,495	216,579	331,844	215,077	130,787
Stocks		0	0	0	0	0
Debtors		2,101	10,669	12,063	12,063	12,063
Cash		263,228	205,591	315,309	198,542	114,252
Other		166	319	4,472	4,472	4,472
Current Liabilities		(30,794)	(44,495)	(50,588)	(37,484)	(37,484)
Creditors		(30,794)	(40,179)	(37,484)	(37,484)	(37,484)
Deferred revenue		0	(4,316)	(13,104)	0	0
Short term borrowings		0	0	0	0	0
Long Term Liabilities		(216,610)	(197,113)	(202,858)	(186,479)	(170,303)
Long term borrowings		(81,334)	(56,361)	(56,617)	(40,441)	(24,265)
Other long term liabilities		(135,276)	(140,752)	(146,241)	(146,038)	(146,038)
Net Assets		515,846	478,848	630,266	543,503	475,874
<b>CASH FLOW</b>						
Operating Cash Flow		108,229	(65,204)	(67,716)	(93,520)	(93,626)
Net Interest		2,790	9,308	10,338	10,277	6,256
Tax		0	(7,038)	3,297	3,000	4,304
Capex		(462)	(1,983)	(1,224)	(1,224)	(1,224)
Acquisitions/disposals		0	0	0	(35,300)	0
Financing		126,093	4,883	169,349	0	0
Dividends		0	0	0	0	0
Other		2,386	(3,015)	(3,818)	0	0
Net Cash Flow		239,036	(63,049)	110,226	(116,767)	(84,290)
Opening net debt/(cash)		(32,049)	(263,228)	(205,591)	(315,309)	(198,542)
HP finance leases initiated		0	0	0	0	0
Other		(7,857)	5,412	(508)	0	0
Closing net debt/(cash)		(263,228)	(205,591)	(315,309)	(198,542)	(114,252)

Source: Mesoblast accounts, Edison Investment Research. Note: Revenue is adjusted to exclude interest income, per IFRS.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Mesoblast and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2014. "FTSE" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Frankfurt +49 (0)69 78 8076 960  
Schumannstrasse 34b  
60325 Frankfurt  
Germany

London +44 (0)20 3077 5700  
280 High Holborn  
London, WC1V 7EE  
United Kingdom

New York +1 646 653 7026  
245 Park Avenue, 39th Floor  
10167, New York  
US

Sydney +61 (0)2 9258 1161  
Level 25, Aurora Place  
88 Phillip St, Sydney  
NSW 2000, Australia

Wellington +64 (0)48 948 555  
Level 15, 171 Featherston St  
Wellington 6011  
New Zealand